Francesco Sclafani1, Gina Hesselberg2, Stephen R Thompson3,4, Philip Truskett3,5, Koroush Haghighi3,5, Sheela Rao1, David Goldstein3,6. 1. Department of Medicine, The Royal Marsden NHS Foundation Trust, London, Surrey, UK. 2. Department of Radiation Oncology, St. George Hospital, Sydney, New South Wales, Australia. 3. Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia. 4. Department of Radiation Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia. 5. Department of General Surgery, Prince of Wales Hospital, Sydney, New South Wales, Australia. 6. Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Abstract
BACKGROUND AND OBJECTIVES: There is limited evidence to guide the management of patients with oligometastatic anal squamous cell carcinoma (SCC). We aimed to address this question by reporting the outcome of SCC patients who were treated with organ-directed therapies at two large cancer centers. METHODS: Patients with advanced anal SCC who were treated with surgery, stereotactic radiotherapy, or radiofrequency ablation (RFA) with a curative intent from 2008 to 2017 were retrospectively identified from the institutional electronic patient records. RESULTS: Eight patients with liver or lung metastases met the study inclusion criteria. Seven were treated with surgery while one received RFA and radiotherapy. Median progression-free survival was 5 months (range, 4-39). Three patients underwent repeat organ-directed treatment upon failure of the initial surgery with no evidence of further recurrent disease at the last follow-up. Median overall survival from the time of the first organ-directed therapy was 31 months (range, 11-96) with two out of eight patients being alive and disease-free at 5 years. CONCLUSIONS: Our study confirms that consideration should be given to the adoption of a multidisciplinary treatment approach in carefully selected, oligometastatic anal SCC patients as organ-directed therapies may offer the chance of achieving a relatively long disease control.
BACKGROUND AND OBJECTIVES: There is limited evidence to guide the management of patients with oligometastatic anal squamous cell carcinoma (SCC). We aimed to address this question by reporting the outcome of SCCpatients who were treated with organ-directed therapies at two large cancer centers. METHODS:Patients with advanced anal SCC who were treated with surgery, stereotactic radiotherapy, or radiofrequency ablation (RFA) with a curative intent from 2008 to 2017 were retrospectively identified from the institutional electronic patient records. RESULTS: Eight patients with liver or lung metastases met the study inclusion criteria. Seven were treated with surgery while one received RFA and radiotherapy. Median progression-free survival was 5 months (range, 4-39). Three patients underwent repeat organ-directed treatment upon failure of the initial surgery with no evidence of further recurrent disease at the last follow-up. Median overall survival from the time of the first organ-directed therapy was 31 months (range, 11-96) with two out of eight patients being alive and disease-free at 5 years. CONCLUSIONS: Our study confirms that consideration should be given to the adoption of a multidisciplinary treatment approach in carefully selected, oligometastatic anal SCCpatients as organ-directed therapies may offer the chance of achieving a relatively long disease control.
Authors: J Engstrand; L F Abreu de Carvalho; D Aghayan; A Balakrishnan; A Belli; B Björnsson; B V M Dasari; O Detry; M Di Martino; B Edwin; J Erdmann; R Fristedt; G Fusai; T Gimenez-Maurel; O Hemmingsson; C Hidalgo Salinas; B Isaksson; A Ivanecz; F Izzo; W T Knoefel; P Kron; N Lehwald-Tywuschik; M Lesurtel; J P A Lodge; N Machairas; M V Marino; V Martin; A Paterson; J Rystedt; P Sandström; A Serrablo; A K Siriwardena; H Taflin; T M van Gulik; S Yaqub; I Özden; J M Ramia; C Sturesson Journal: BJS Open Date: 2021-07-06